| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 6,228.63 | 5,652.62 | 5,305.79 | 5,393.13 | 4,605.75 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 6,228.63 | 5,652.62 | 5,305.79 | 5,393.13 | 4,605.75 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 28.31 | 2.74 | 55.74 | 87.29 | 40.36 |
Total Income | 6,256.94 | 5,655.36 | 5,361.53 | 5,480.42 | 4,646.11 |
Total Expenditure | 5,296.25 | 4,975.17 | 4,431.63 | 3,912.85 | 3,461.8 |
PBIDT | 960.69 | 680.19 | 929.9 | 1,567.57 | 1,184.31 |
Interest | 56.19 | 50.17 | 17.73 | 16.02 | 27.16 |
PBDT | 904.5 | 630.02 | 912.17 | 1,551.55 | 1,157.15 |
Depreciation | 272.67 | 275.43 | 286.78 | 183.47 | 157.32 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 62.06 | 3.41 | 127.93 | 262.88 | 203.48 |
Deferred Tax | -46.05 | 9.19 | -23.48 | -9.56 | -4.3 |
Reported Profit After Tax | 615.82 | 341.99 | 520.94 | 1,114.76 | 800.65 |
Minority Interest After NP | 0 | 0 | 0 | -31.61 | -28.12 |
Net Profit after Minority Interest | 615.82 | 341.99 | 520.94 | 1,178.11 | 828.82 |
Extra-ordinary Items | 0 | 0 | 0 | 0 | -34.76 |
Adjusted Profit After Extra-ordinary item | 615.82 | 341.99 | 520.94 | 1,178.11 | 863.58 |
EPS (Unit Curr.) | 30.78 | 17.4 | 26.5 | 60.81 | 43.97 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 550 | 400 | 500 | 700 | 500 |
Equity | 39.31 | 39.31 | 39.31 | 39.31 | 37.7 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 15.42 | 12.03 | 17.52 | 29.06 | 25.71 |
PBDTM(%) | 14.52 | 11.14 | 17.19 | 28.76 | 25.12 |
PATM(%) | 9.88 | 6.05 | 9.81 | 20.67 | 17.38 |
The approved product is the generic equivalent of Tegretol Tablets 200 mg, which was initially developed by Novartis Pharmaceuticals Corporation.
This approval bolsters Alembic's portfolio in the United States market and reinforces its presence in injectable segment
Following an inspection carried out from Nov 14-22 2024, the facility was cited as being ‘VAI’ (Voluntary Action Indicated).
EBITDA margin came in at 15.4% in the quarter under review as compared to 16.30% in the previous corresponding period.
The authorised ANDA is a therapeutic equivalent of the reference-listed drug (RLD), Corlanor tablets, in the same 5 mg and 7.5 mg dosages.
These medications are also used to treat chronic stable angina and angina induced by coronary artery spasm.
Alembic Pharmaceuticals continues to grow its footprint in the US, with this approval contributing to its robust portfolio of generic medications.
The business stated that the authorised ANDA is therapeutically similar to the reference-listed drug product (RLD) Lastacaft Solution.
The approved Lamotrigine Extended-Release tablets are therapeutic equivalents of GlaxoSmithKline's Lamictal XR, with strengths of 200 mg, 250 mg, and 300 mg.
Alembic Pharmaceuticals has got the final approval from USFDA for Dabigatran Etexilate Capsules, 110 mg.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
